John O Andrew - 29 Jan 2026 Form 3 Insider Report for Polaryx Therapeutics, Inc. (PLYX)

Reporting relationship: Chief Investment Officer
Issuer ticker: PLYX
Reported as of: 29 Jan 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 29 Jan 2026, 16:43:08 UTC
Source filing: View source filing
Reporting owner signature: /s/ G. Michael Landis, as attorney-in-fact for Andrew John O

Key filing fact

John O Andrew filed Form 3 for Polaryx Therapeutics, Inc. (PLYX) on 29 Jan 2026.

Key facts

This page summarizes John O Andrew's Form 3 filing for Polaryx Therapeutics, Inc. (PLYX).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 29 Jan 2026, 16:43.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002103158 Primary reporting owner

O Andrew John

Relationship: Chief Investment Officer
Address: SOUTH TOWER, 140 E RIDGEWOOD AVENUE,, SUITE 415, PARAMUS
Signature: /s/ G. Michael Landis, as attorney-in-fact for Andrew John O
Signature date: 29 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PLYX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 471,808
Date: 29 Jan 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Includes (i) 28,875 restricted stock units ("RSUs"), which will vest on March 1, 2026, (ii) 115,500 RSUs, which will vest in two equal installments on November 1, 2026 and November 1, 2027 and (iii) 175,000 RSUs, which will vest in four equal installments on September 1, 2026, September 1, 2027, September 1, 2028 and September 1, 2029, in each case subject to the Reporting Person's continued service to the Issuer or its subsidiaries, Mstone Partners Healthcare Limited or its affiliates, or Curestone Partners Platform Limited or its affiliates. The RSUs are not deliverable unless and until the Issuer consummates a change in control within seven years of the grant date of such RSUs.

SEC remarks

Exhibit 24 - Power of Attorney